Vivimed Labs Latest Share Price (VIVIMEDLAB)
TODAY IN ONE LINE
With a market cap of ₹55.39 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Vivimed Labs flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Price MomentumStock underperformed, dropping 46.2% over 1Y
- ●Low Promoter HoldingPromoters hold only 7.6%
Latest Vivimed Labs News
What changed recently?
Recent events, corporate actions, and announcements.
Vivimed Labs Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Vivimed Labs Limited, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Vivimed Labs Limited technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for Vivimed Labs Limited — derived from the latest tape, not yesterday's close.
Vivimed Labs Limited last traded at ₹7.39 with an intraday range of ₹7.36–₹7.79 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹7.39| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 8.53 | +1.14 | +15.38% |
| R3 | 8.10 | +0.71 | +9.56% |
| R2 | 7.94 | +0.55 | +7.49% |
| R1 | 7.67 | +0.28 | +3.74% |
| PIVOT | 7.51 | 0.12 | 1.67% |
| CURRENT | 7.39 | — | — |
| S1 | 7.24 | -0.15 | -2.07% |
| S2 | 7.08 | -0.31 | -4.15% |
| S3 | 6.81 | -0.58 | -7.89% |
| S4 | 6.38 | -1.01 | -13.71% |
VIVIMEDLAB is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹–₹
Trading Inside opening range
Vivimed Labs Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Vivimed Labs Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Vivimed Labs Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹55.39 Cr. and reported EPS of ₹-2.92.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 116 | 70 ▼ 39.8% |
| Sales Growth YoY %Derived | -22.00% | -39.80% |
| Other Income | 4 | 6 ▲ 44.6% |
| Total Income | 121 | 76 ▼ 36.7% |
| 60 | 74 ▲ 23.2% | |
| Gross ProfitDerived | 56 | -4 ▼ 106.7% |
| Gross Margin %Derived | 48.52% | -5.37% |
| 69 | 148 ▲ 113.9% | |
| EBITDA (Operating Profit)Derived | -13 | -151 ▼ 1102.6% |
| OPM %Derived | -10.82% | -216.24% |
| 23 | 30 ▲ 30.4% | |
| Profit Before Tax (PBT) | -31 | -175 ▼ 458.4% |
| 0 | 0 ▲ 21.2% | |
| Effective Tax %Derived | -0.36% | -0.08% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | -31 | -175 ▼ 456.8% |
| Less: Non-controlling Interests | — | — |
| Net Profit (Owner's PAT)Derived | -31 | -175 ▼ 456.8% |
| Net Profit Margin %Derived | -27.09% | -250.59% |
| PAT Growth YoY %Derived | 30.69% | -456.81% |
| Earnings Per Share (EPS ₹) | -3.80 | -21.15 ▼ 456.6% |
| Diluted Shares Outstanding (Cr) | 8 | 8 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | — | — |
| Total Expenses (incl. D&A & Interest) | 152 | 252 ▲ 65.5% |
| Material Cost % of RevenueDerived | 49.68% | 47.02% |
| Employee Cost % of RevenueDerived | 24.42% | 35.67% |
| Other Cost % of RevenueDerived | 34.93% | 175.20% |
| Interest Coverage (x)Derived | -11.13x | -42.54x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,186 | 1,315 ▲ 10.9% | 1,059 ▼ 19.5% | 861 ▼ 18.6% | 237 ▼ 72.5% | 187 ▼ 21.2% | 149 ▼ 20.3% | 116 ▼ 22.0% | 70 ▼ 39.8% | |
| Sales Growth YoY %Derived | — | 10.92% | -19.49% | -18.64% | -72.46% | -21.15% | -20.33% | -22.00% | -39.80% | |
| Other Income | 10 | 23 ▲ 138.9% | 8 ▼ 64.0% | 10 ▲ 19.0% | 1 ▼ 87.1% | 1 ▼ 23.8% | 10 ▲ 930.6% | 4 ▼ 56.2% | 6 ▲ 44.6% | |
| Total Income | 1,195 | 1,338 ▲ 12.0% | 1,067 ▼ 20.3% | 871 ▼ 18.3% | 239 ▼ 72.6% | 188 ▼ 21.2% | 159 ▼ 15.4% | 121 ▼ 24.1% | 76 ▼ 36.7% | |
480 | 518 ▲ 8.1% | 463 ▼ 10.8% | 355 ▼ 23.4% | 153 ▼ 56.7% | 272 ▲ 76.9% | 71 ▼ 73.7% | 60 ▼ 16.3% | 74 ▲ 23.2% | ||
| Gross ProfitDerived | 706 | 797 ▲ 12.9% | 596 ▼ 25.2% | 507 ▼ 15.0% | 84 ▼ 83.5% | -84 ▼ 200.7% | 78 ▲ 191.9% | 56 ▼ 27.3% | -4 ▼ 106.7% | |
| Gross Margin %Derived | 59.54% | 60.58% | 56.31% | 58.85% | 35.32% | -45.12% | 52.05% | 48.52% | -5.37% | |
494 | 620 ▲ 25.4% | 588 ▼ 5.1% | 483 ▼ 17.8% | 92 ▼ 81.0% | 103 ▲ 12.0% | 111 ▲ 7.9% | 69 ▼ 37.8% | 148 ▲ 113.9% | ||
| EBITDA (Operating Profit)Derived | 212 | 177 ▼ 16.4% | 8 ▼ 95.4% | 24 ▲ 193.4% | -8 ▼ 133.9% | -187 ▼ 2223.8% | -33 ▲ 82.2% | -13 ▲ 62.3% | -151 ▼ 1102.6% | |
| OPM %Derived | 17.88% | 13.47% | 0.77% | 2.76% | -3.40% | -100.11% | -22.42% | -10.82% | -216.24% | |
136 | 134 ▼ 1.4% | 126 ▼ 6.1% | 109 ▼ 13.1% | 58 ▼ 46.9% | 144 ▲ 148.6% | 22 ▼ 84.5% | 23 ▲ 3.6% | 30 ▲ 30.4% | ||
| Profit Before Tax (PBT) | 86 | 66 ▼ 22.9% | -109 ▼ 265.8% | -76 ▲ 30.8% | -65 ▲ 14.4% | -331 ▼ 410.0% | -46 ▲ 86.1% | -31 ▲ 31.5% | -175 ▼ 458.4% | |
10 | 9 ▼ 9.8% | -0 ▼ 104.1% | 2 ▲ 664.5% | 3 ▲ 38.8% | -2 ▼ 175.2% | -0 ▲ 82.2% | 0 ▲ 130.0% | 0 ▲ 21.2% | ||
| Effective Tax %Derived | 11.23% | 13.14% | 0.33% | -2.68% | -4.34% | 0.64% | 0.82% | -0.36% | -0.08% | |
| Profit/Loss from Discontinued Ops | 2 | 57 ▲ 2996.0% | — ▼ 100.0% | — | — | — | — | — | — | |
| Total Profit for Period | 76 | 57 ▼ 24.6% | -109 ▼ 290.2% | -78 ▲ 28.7% | -68 ▲ 13.0% | -329 ▼ 385.6% | -45 ▲ 86.2% | -31 ▲ 30.7% | -175 ▼ 456.8% | |
| Less: Non-controlling Interests | -2 | — ▲ 100.0% | — | — | — | — | — | — | — | |
| Net Profit (Owner's PAT)Derived | 78 | 57 ▼ 26.4% | -109 ▼ 290.2% | -78 ▲ 28.7% | -68 ▲ 13.0% | -329 ▼ 385.6% | -45 ▲ 86.2% | -31 ▲ 30.7% | -175 ▼ 456.8% | |
| Net Profit Margin %Derived | 6.57% | 4.36% | -10.31% | -9.03% | -28.51% | -175.59% | -30.49% | -27.09% | -250.59% | |
| PAT Growth YoY %Derived | — | -26.40% | -290.21% | 28.70% | 13.04% | -385.64% | 86.17% | 30.69% | -456.81% | |
| Earnings Per Share (EPS ₹) | 9.44 | 13.90 ▲ 47.2% | -13.16 ▼ 194.7% | -9.38 ▲ 28.7% | -8.16 ▲ 13.0% | -39.56 ▼ 384.8% | -5.48 ▲ 86.1% | -3.80 ▲ 30.7% | -21.15 ▼ 456.6% | |
| Diluted Shares Outstanding (Cr) | 8 | 8 ▲ 0.0% | 8 ▲ 0.5% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -1 | — ▲ 100.0% | — | — | — | 1 | 1 ▲ 0.7% | — ▼ 100.0% | — | |
| Total Expenses (incl. D&A & Interest) | 1,110 | 1,272 ▲ 14.6% | 1,177 ▼ 7.5% | 947 ▼ 19.5% | 303 ▼ 68.0% | 519 ▲ 71.0% | 205 ▼ 60.5% | 152 ▼ 25.8% | 252 ▲ 65.5% | |
| Material Cost % of RevenueDerived | 41.31% | 42.73% | 45.64% | 41.39% | 64.48% | 58.77% | 60.07% | 49.68% | 47.02% | |
| Employee Cost % of RevenueDerived | 16.68% | 18.38% | 22.04% | 22.71% | 15.27% | 17.46% | 22.91% | 24.42% | 35.67% | |
| Other Cost % of RevenueDerived | 24.98% | 28.73% | 33.51% | 33.37% | 23.45% | 37.54% | 51.56% | 34.93% | 175.20% | |
| Interest Coverage (x)Derived | 1.96x | 1.64x | -1.00x | -0.59x | -0.66x | -8.24x | -21.94x | -11.13x | -42.54x |
Vivimed Labs segment analysis : revenue and profit mix.
Disclosed business segments at Vivimed Labs with their share of revenue and profit, switchable between consolidated and standalone reporting.
Vivimed Labs discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Vivimed Labs Limited.
Our AI distills the core fundamental drivers supporting Vivimed Labs Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Vivimed Labs Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Vivimed Labs Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Vivimed Labs Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Vivimed Labs Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Vivimed Labs Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Vivimed Labs Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Vivimed Labs Limited stood at 74.0% of traded volume, against a 20-day average of 85.0%.
Vivimed Labs announcements: results, concalls, ratings, M&A.
Filings Vivimed Labs sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Vivimed Labs files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 52 documents below.
Corporate Insolvency Resolution Process
Vivimed Labs Limited has informed the Exchange about Corporate Insolvency Resolution Process
Clarification - Financial Results
The Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing…
Updates
Vivimed Labs Limited has informed the Exchange regarding 're lodgment'.
General Updates
Vivimed Labs Limited has informed the Exchange about General Updates
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Vivimed Labs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Vivimed Labs dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Vivimed Labs has declared, sequenced by announce and record date.
Vivimed Labs corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Vivimed Labs Limited: business, sector, key facts.
What Vivimed Labs Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Vivimed Labs Limited operates in the Pharmaceuticals industry under the Healthcare sector.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B Blackbio DX (3BBLACKBIO) Share PricePeer
- Abbott India (ABBOTINDIA) Share PricePeer
- Acutaas Chemicals (ACUTAAS) Share PricePeer
- Anlon Healthcare (AHCL) Share PricePeer
- Amanta Healthcare (AMANTA) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Vivimed Labs Limited (VIVIMEDLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Vivimed Labs Limited (VIVIMEDLAB)?
The current share price of Vivimed Labs Limited (VIVIMEDLAB) is ₹7.39. Today, the stock has declined by ₹0.24 (3.15%), trading in a range of ₹7.36 to ₹7.79. The stock opened at ₹7.63 with a trading volume of 1,46,861 shares.
02What is the 52-week high and low price of Vivimed Labs Limited stock?
The 52-week high price of Vivimed Labs Limited (VIVIMEDLAB) is ₹20.59, while the 52-week low is ₹5.15. Currently trading at ₹7.39, the stock is 43.5% above its 52-week low and 64.11% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
03What is the dividend yield of Vivimed Labs Limited and when is the next dividend?
Vivimed Labs Limited offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹7.39, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹0.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
04How is Vivimed Labs Limited stock performing today in the market?
Vivimed Labs Limited stock opened at ₹7.63 and is currently trading at ₹7.39, showing a decline of ₹0.24 (3.15%). The intraday high is ₹7.79 and low is ₹7.36. The trading volume stands at 1,46,861 shares, indicating moderate market participation today.
05What is the market capitalization of Vivimed Labs Limited?
Vivimed Labs Limited has a market capitalization of ₹55.39 Cr., making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹7.39) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
06What is the ROE and ROCE of Vivimed Labs Limited?
Vivimed Labs Limited has a Return on Equity (ROE) of 0% and Return on Capital Employed (ROCE) of 0%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
07Which sector and industry does Vivimed Labs Limited belong to?
Vivimed Labs Limited operates in the Healthcare sector and belongs to the Pharmaceuticals industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
08What is the sales and profit growth of Vivimed Labs Limited?
Vivimed Labs Limited has reported a sales growth of -22.42% and profit growth of 0%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
The data, ratios and commentary about Vivimed Labs Limited (VIVIMEDLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.